Search

everythinglearnresearchcommunity

for

Search:↓

New product Tomorrowlabs HSF targets hair loss through HIF pathway indirectly by removing scalp iron. Minoxidil and Stemoxydine also relate to HIF pathway.

Hair regrowth and gender transition using finasteride, estrogen, and spironolactone. Significant hair regrowth and personal transformation were achieved through hormone replacement therapy.

ABS-201 shows promise for male hair regrowth by blocking the prolactin receptor, with higher expected efficacy than current treatments. The discussion also covers dosing differences between macaques and humans for hmi115, highlighting a significant dosage disparity.

The conversation discusses the potential of Replicel/Shiseido treatment for hair loss, questioning its effectiveness, whether it grows new follicles, and its market release timeline. It also compares Replicel to other competitors like Kyocera/RIKEN/Tsuji.

The conversation is about the availability of Koshine826 PRO 1% for hair loss treatment. The discussion includes Minoxidil, finasteride, and RU58841.

User reports 12-week progress with HIMS spray, Minoxidil, micro-needling, and biotin. Notable baby hairs on crown and temples, hoping for further improvement.

The conversation discusses the molecular structures of compounds that reduce DHT levels, including finasteride and Ashwagandha. It explores the potential of using Ashwagandha topically as a 5a reductase inhibitor.

HMI-115, a potential treatment for hair loss that has been reported to produce significant regrowth in bald areas. It is the closest thing to a cure currently available and has raised hope that it could make hair transplants obsolete.

Hair growth can be induced without stopping DHT, as seen with Minoxidil. HMI115 may work by promoting follicle growth, not targeting the root cause of hair loss (DHT).

User discusses potential hair loss treatment SCUBE3 and shares mixed opinions on its effectiveness. One user reports positive results after applying SCUBE3 following microneedling.

SCUBE3 is a potential hair loss treatment that people are hopeful about. It may provide a solution without the side effects of finasteride.

The conclusion of the conversation is that the user "Shakalakaplaka" shares their comprehensive hair loss regimen, which includes various treatments targeting different pathways such as DHT, inflammation, fibrosis, immune system, testosterone, gut problems, and scalp health. The effectiveness of the regimen is not confirmed, and some users express skepticism or request before and after pictures for credibility.

The progress of Phase I of HMI-115, a potential hair loss treatment, which consists of Minoxidil, finasteride, and RU58841. The estimated completion date is June.

Diffuse thinners find shopping challenging due to harsh overhead lighting, but H&M's side lighting in fitting rooms is more flattering. Many users humorously suggest banning overhead lighting to improve the shopping experience.

The conversation discusses the delay in the release of GT20029 for hair loss treatment and skepticism about its effectiveness. Participants mention other treatments like verteporfin and advancements in transplant procedures as more realistic options.

A 46-year-old male shared his 3-week progress using HIMS serum with Finasteride 0.3% and Minoxidil 6%, showing improvement without noticeable shedding. His routine includes vitamins, a healthy diet, and specific hair care practices like microneedling and using caffeine solution.

A user is concerned about hair shedding despite noticeable regrowth after 7 months of using finasteride. The dermatologist confirmed positive results, but the user remains skeptical and confused.

A 16-year-old is experiencing hair loss and is using minoxidil, finasteride, and plans to add RU58841, while considering other treatments like MK-677 and microneedling. Concerns are raised about the potential impact of these treatments on puberty and development.

A user switched from finasteride to dutasteride and experienced continuous shedding but is now seeing some regrowth. Others shared similar experiences, noting that shedding can continue but hair often improves over time with dutasteride.

New hair loss treatments PP405 and VDPHL01 are discussed with skepticism and hope, alongside existing treatments like minoxidil and finasteride. Users express frustration over limited progress since the 1980s but remain cautiously optimistic.

Replicel's results were delayed, but Shiseido might share data at BioJapan on October 11. Users are hopeful for new treatments like RCH-01, potentially eliminating the need for finasteride or minoxidil.

A European individual planning to go to China is seeking information on how to participate in HMI-115 trials for Androgenetic Alopecia. They've tried contacting Mrs. Yang and Mr. Wang for assistance but haven't received a response.

A user is experiencing significant hair loss and stress, seeking advice on treatments. They are using Pura d'or shampoo and conditioner, biotin, and considering other options but are hesitant about treatments like Minoxidil due to the need for continuous use.

The user is concerned about the quick prescription process for hair loss treatments like Minoxidil and Finasteride through HIMs, questioning the lack of a thorough evaluation. Another user reassures that such practices are common, emphasizing the effectiveness and low risk of these treatments, and suggests monitoring personal response to the medication.

An 18-year-old male using minoxidil and finasteride is experiencing increased hair loss, possibly due to a shedding phase from finasteride. He also takes zinc, magnesium, calcium, and vitamin C, and is concerned about hair loss from his temples.

The conversation is about the delay in receiving updates on the HMI-115 phase 1 trial for hair loss. No specific treatments are mentioned in the conversation.

A new hair loss treatment theory beyond minoxidil and finasteride is proposed, causing mixed reactions in the community, with some members eager to explore and support it, while others call for more research and evidence.

Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. HMI-115, a monoclonal antibody drug, is in phase 1 and 2 trials for different conditions, but its availability on the gray market is unlikely due to high production costs.

KOSHINE826 is a new anti-hair loss and hair growth solution that claims to effectively control oil, reduce hair fall, and promote real hair growth. It targets androgenetic alopecia by inhibiting DHT and has shown promising results in clinical trials.

HMI-115 shows promising hair growth and thickening in just 2 months. Results are positive but need more time for confirmation.